Xenon(XENE)
$41.00-1.11 (-2.62%)
XENE
Xenon stock drug pipeline
$41.00
At close:-1.11 (-2.62%)
Want to see XENE full AI Analyst Report?
Xenon (XENE) Drug Pipeline
510 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Azetukalner | Bipolar Depression, Bipolar Disorder, Bipolar I Disorder, Bipolar Ii Disorder | Phase III | Enrolling By Invitation | An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE) | Oct 14, 2025 | ― |
| Azetukalner | Bipolar Depression, Bipolar Disorder, Bipolar I Disorder, Bipolar Ii Disorder | Phase III | Recruiting | A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) | Sep 08, 2025 | ― |
| Azetukalner | Major Depressive Disorder | Phase III | Recruiting | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | Jul 14, 2025 | ― |
| Azetukalner | Major Depressive Disorder | Phase III | Enrolling By Invitation | An Open-Label Study of Azetukalner in Major Depressive Disorder | Mar 20, 2025 | ― |
| Azetukalner | Major Depressive Disorder | Phase III | Recruiting | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder | Jan 09, 2025 | ― |
| Xen1101 | Focal Onset Seizures | Phase III | Recruiting | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) | Jan 26, 2023 | ― |
| Xen1101 | Focal Epilepsy, Tonic-Clonic Seizures | Phase III | Enrolling By Invitation | An Open-label Study of XEN1101 in Epilepsy | Jan 13, 2023 | ― |
| Xen1101 | Primary Generalized Tonic-Clonic Seizures | Phase III | Recruiting | A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures | Dec 19, 2022 | ― |
| Xen1101 | Focal Onset Seizures | Phase III | Active Not Recruiting | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures | Nov 06, 2022 | ― |
| Xen496 | Epilepsy, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Epilepsy In Children, Epilepsy; Seizure, Disease, Epileptic Syndromes | Phase III | Terminated | An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE | May 03, 2021 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Azetukalner | Phase III | Bipolar Depression, Bipolar Disorder, Bipolar I Disorder, Bipolar Ii Disorder | Enrolling By Invitation | An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE) | Oct 14, 2025 | ― |
| Azetukalner | Phase III | Bipolar Depression, Bipolar Disorder, Bipolar I Disorder, Bipolar Ii Disorder | Recruiting | A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) | Sep 08, 2025 | ― |
| Azetukalner | Phase III | Major Depressive Disorder | Recruiting | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | Jul 14, 2025 | ― |
| Azetukalner | Phase III | Major Depressive Disorder | Enrolling By Invitation | An Open-Label Study of Azetukalner in Major Depressive Disorder | Mar 20, 2025 | ― |
| Azetukalner | Phase III | Major Depressive Disorder | Recruiting | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder | Jan 09, 2025 | ― |
| Xen1101 | Phase III | Focal Onset Seizures | Recruiting | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) | Jan 26, 2023 | ― |
| Xen1101 | Phase III | Focal Epilepsy, Tonic-Clonic Seizures | Enrolling By Invitation | An Open-label Study of XEN1101 in Epilepsy | Jan 13, 2023 | ― |
| Xen1101 | Phase III | Primary Generalized Tonic-Clonic Seizures | Recruiting | A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures | Dec 19, 2022 | ― |
| Xen1101 | Phase III | Focal Onset Seizures | Active Not Recruiting | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures | Nov 06, 2022 | ― |
| Xen496 | Phase III | Epilepsy, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Epilepsy In Children, Epilepsy; Seizure, Disease, Epileptic Syndromes | Terminated | An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE | May 03, 2021 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Xenon Pharmaceuticals (XENE) have in its pipeline
Xenon XENE is currently developing the following drugs: Azetukalner, Xen1101, Xen496. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
